Zymeworks BC Inc. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 06/30/22 Q2

ended 03/31/22 Q1

ended 12/31/21 FY 2021 – amended

ended 12/31/21 FY 2021

ended 09/30/21 Q3

Prospectuses and Registrations Filter

Securities registration termination

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Bank of America Corporation

Wellington Management Group Llp

Redmile Group, LLC

Moore Paul Andrew

News Filter

Material Definitive Agreement, Termination of Material Definitive Agreement, Financial Statements or Exhibits

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Other Events, Financial Statements or Exhibits

Material Definitive Agreement, Termination of Material Definitive Agreement, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Other Events

(The “Company”) Special Meeting of Securityholders October 7, 2022

Proxies Filter

Proxy related to merger

Definitive proxy

Definitive proxy

Definitive proxy

Other Filter

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Confidential treatment order